Halozyme Therapeutics, Inc.
US ˙ NasdaqGS ˙ US40637H1095

SecurityHALO / Halozyme Therapeutics, Inc.
InstitutionMacquarie Group Ltd
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Macquarie Group Ltd closes position in HALO / Halozyme Therapeutics, Inc.

On February 13, 2026 - Macquarie Group Ltd filed a 13F-HR form disclosing ownership of 0 shares of Halozyme Therapeutics, Inc. (US:HALO) valued at $0 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 13, 2025 disclosing 1,546,185 shares of Halozyme Therapeutics, Inc.. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 0 -100.00 0
2025-11-13 2025-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 1,546,185 -537,207 -25.79 113,397 4.63 0.1324
2025-08-14 2025-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 2,083,392 -590,881 -22.10 108,378 -36.49 0.1329
2025-08-14 2025-03-31 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 2,674,273 -231,212 -7.96 170,645 22.84 0.2118
2025-05-15 2025-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 2,674,273 -231,212 170,645 0.1394
2025-02-14 2024-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 2,905,485 -105,340 -3.50 138,911 -19.40 0.1685
2024-11-14 2024-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 3,010,825 -66,702 -2.17 172,340 6.95 0.1860
2024-08-09 2024-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 3,077,527 86,402 2.89 161,139 32.43 0.1848
2024-05-14 2024-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 2,991,125 -291,515 -8.88 121,679 0.29 0.1380
2024-02-14 2023-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 3,282,640 -161,550 -4.69 121,326 -7.78 0.1402
2023-11-14 2023-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 3,444,190 134,835 4.07 131,568 10.22 0.1653
2023-10-27 2023-06-30 13F/A-2 HALOZYME THERAPEUTICS COM 40637H109 3,309,355 108,874 3.40 119,368 -2.34 0.1365
2023-10-12 2023-06-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 3,309,355 108,874 119,368 0.1200
2023-08-14 2023-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 3,309,355 108,874 119,368 0.1211
2023-06-01 2023-03-31 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 3,200,481 595,220 22.85 122,226 -17.55 0.1452
2023-05-15 2023-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 3,200,481 595,220 122,226 0.1122
2023-02-21 2022-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 2,605,261 50,294 1.97 148,239 46.68 0.1751
2022-11-14 2022-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 2,554,967 34,436 1.37 101,065 -8.87 0.1240
2022-08-17 2022-06-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 2,520,531 45,885 1.85 110,903 12.38 0.1245
2022-08-15 2022-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 2,520,531 45,885 110,903 0.0397
2022-05-16 2022-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 2,474,646 -598,310 -19.47 98,689 -20.13 0.0751
2022-02-11 2021-12-31 13F Halozyme Therapeutics COM 40637H109 3,072,956 80,889 2.70 123,564 1.52 0.1030
2021-11-12 2021-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 2,992,067 50,129 1.70 121,717 -8.89 0.1037
2021-08-13 2021-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 2,941,938 731,878 33.12 133,593 44.99 0.1097
2021-05-14 2021-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 2,210,060 -107,992 -4.66 92,138 -6.94 0.1303
2021-02-16 2020-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 2,318,052 171,548 7.99 99,004 75.51 0.1446
2020-11-13 2020-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 2,146,504 1,910,555 809.73 56,410 791.86 0.0955
2020-08-11 2020-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 235,949 1,385 0.59 6,325 49.88 0.0109
2020-05-15 2020-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 234,564 4,564 1.98 4,220 3.48 0.0087
2020-03-18 2019-12-31 13F/A-2 HALOZYME THERAPEUTICS COM 40637H109 230,000 0 0.00 4,078 14.33 0.0058
2020-02-28 2019-12-31 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 230,000 0 4,078 0.0059
2020-02-14 2019-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 230,000 0 4,078 5,117.5444
2019-11-14 2019-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 230,000 0 0.00 3,567 -9.72 0.0060
2019-11-06 2019-06-30 13F/A-2 HALOZYME THERAPEUTICS COM 40637H109 230,000 -170,000 -42.50 3,951 -38.65 0.0067
2019-09-24 2019-06-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 230,000 0 3,951 0.0067
2019-08-14 2019-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 230,000 -170,000 3,951
2019-05-15 2019-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 400,000 -100,000 -20.00 6,440 -11.96 0.0110
2019-02-15 2018-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 500,000 0 0.00 7,315 -19.48 0.0141
2018-11-15 2018-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 500,000 0 0.00 9,085 7.71 0.0148
2019-03-21 2018-06-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 500,000 0 0.00 8,435 -13.88 0.0145
2018-08-14 2018-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 500,000 0 8,435
2018-05-11 2018-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 500,000 -4,100 -0.81 9,795 -4.09 0.0178
2018-02-14 2017-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 504,100 4,100 0.82 10,213 17.59 0.0181
2017-11-08 2017-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 500,000 0 0.00 8,685 35.49 0.0156
2017-08-14 2017-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 500,000 40,000 8.70 6,410 7.51 0.0117
2017-05-15 2017-03-31 13F Halozyme Therapeutics COM 40637H109 460,000 0 0.00 5,962 31.18 0.0108
2017-03-30 2016-12-31 13F/A-1 Halozyme Therapeutics COMMON 40637H109 460,000 155,200 50.92 4,545 23.44 0.0087
2017-02-15 2016-12-31 13F Halozyme Therapeutics COMMON 40637H109 460,000 4,545
2016-11-15 2016-09-30 13F HALOZYME THERAPEUTICS COMMON 40637H109 304,800 0 0.00 3,682 40.00 0.0071
2016-09-14 2016-06-30 13F/A-1 HALOZYME THERAPEUTICS COMMON 40637H109 304,800 0 0.00 2,630 -8.87 0.0052
2016-08-15 2016-06-30 13F HALOZYME THERAPEUTICS COMMON 40637H109 304,800 2,630
2016-05-16 2016-03-31 13F HALOZYME THERAPEUTICS COMMON 40637H109 304,800 304,800 2,886 0.0058
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.